A5031718088- Multiple Sclerosis Research Studies
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Peripheral Neuropathies and Disorders
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- RNA and protein synthesis mechanisms
- Bacteriophages and microbial interactions
- Biosimilars and Bioanalytical Methods
- Systemic Lupus Erythematosus Research
- Pharmaceutical studies and practices
- Inflammatory Bowel Disease
- Immunodeficiency and Autoimmune Disorders
- Bacterial Genetics and Biotechnology
- Salivary Gland Disorders and Functions
- Systemic Sclerosis and Related Diseases
- Medical and Biological Ozone Research
- Influenza Virus Research Studies
- DNA and Nucleic Acid Chemistry
- Psoriasis: Treatment and Pathogenesis
- Receptor Mechanisms and Signaling
- Glycosylation and Glycoproteins Research
- Bacterial Infections and Vaccines
- Platelet Disorders and Treatments
- Vascular Malformations and Hemangiomas
Amgen (United States)
2008-2025
Horizon Therapeutics (United States)
2021-2024
Horizon Therapeutics (United Kingdom)
2021-2023
Viventia Bio (Canada)
2020-2021
Mayo Clinic in Arizona
2021
Mayo Clinic
2021
National Cancer Center
2021
Hospices Civils de Lyon
2021
WinnMed
2021
University of California, San Francisco
2021
These studies tested whether antigenic competition between T cells occurs. We generated CD8+ cell responses in H-2b mice against the dominant ovalbumin epitope SIINFEKL (ova8) and subdominant KRVVFDKL, using either vaccinia virus expressing (VV-ova) or peptide-pulsed dendritic cells. were visualized by major histocompatibility complex class I–peptide tetrameric molecules. Transfer of transgenic with high affinity for ova8 (OT1 cells) completely inhibited response host antigen-specific to...
Tezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody, targets thymic stromal lymphopoietin, cytokine that is implicated in the pathogenesis of atopic dermatitis (AD).We sought to evaluate efficacy and safety tezepelumab adults with moderate severe AD.In this phase 2a study (NCT02525094), 113 patients were randomized 1:1 subcutaneous 280 mg or placebo every 2 weeks, plus class 3 topical corticosteroids (TCS). The primary endpoint was week 12 response rate for ≥50% reduction...
MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), cytokine implicated in the pathogenesis of Crohn's disease (CD). We analyzed its safety and efficacy treatment CD phase 2a study.We conducted double-blind, placebo-controlled study 119 adults with moderate to severe failed by tumor necrosis factor antagonists. Patients were randomly assigned (1:1) groups given (700 mg) or placebo intravenously at weeks 0 4. received open-label (210 subcutaneously every 4...
Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spectrum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial fibrillary acidic protein (sGFAP) concentration and NMOSD activity assessed of inebilizumab treatment.N-MOmentum was a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial adults with NMOSD. sGFAP levels were measured by single-molecule arrays...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTBetaine can eliminate the base pair composition dependence of DNA meltingWilliam A. Rees, Thomas D. Yager, John Korte, and Peter H. Von HippelCite this: Biochemistry 1993, 32, 1, 137–144Publication Date (Print):January 12, 1993Publication History Published online1 May 2002Published inissue 12 January 1993https://pubs.acs.org/doi/10.1021/bi00052a019https://doi.org/10.1021/bi00052a019research-articleACS PublicationsRequest reuse permissionsArticle...
Multimeric peptide/class II MHC staining reagents were synthesized and shown to bind with appropriate specificity T cell hybridomas. A small, expanded population of cells detected one these in peptide-immunized C57BL/10 mice persisted for several months. This further on secondary immunization. Equating the extent binding this reagent receptor affinity, we saw little correlation immunizing peptide dose affinity at peak primary response. However, there was an inverse relation between apparent...
During activation T cells are thought to change their patterns of gene expression dramatically. To find out whether this is true for activated in animals, the genes expressed resting and 8 48 hr after were examined by using Affymetrix arrays. Gene arrays gave accurate comparisons different cell types because known vary during changed as expected. Of approximately 6,300 assessed arrays, about one-third appreciable extents any tested. Thus, express a surprisingly large diversity genes. The...
Complexes of Escherichia coli RNA polymerase with DNA containing the λ P L promoter have been deposited on mica and imaged in air a scanning force microscope. The topographic images reveal gross spatial relations relative to template. appears bent open complexes bound more severely elongation which has synthesized 15-nucleotide transcript. This difference could be related conformational changes that accompany maturation into suggests formation complex involves considerable modification between
The cases are presented of 24 patients with various diseases who had negative tuberculin reactions.Whilst treated cortisone or prednisolone in moderate low dosage the reaction became positive at same higher dilutions 20 cases.The -patients were mostly elderly, showed frank signs suprarenal cortical suppression.The suggestion is made that steroid treatment, although able to suppress a when given high dosage, may, lower actually restore which has been suppressed by age, infection,...
VIB7734 depletes plasmacytoid dendritic cells and demonstrates clinical benefit in patients with cutaneous lupus.
Abstract Sjögren’s disease (SjD) is a chronic, systemic autoimmune with no approved disease-modifying therapies. Dazodalibep (DAZ), novel nonantibody fusion protein, CD40 ligand antagonist that blocks costimulatory signals between T and B cells antigen-presenting cells, therefore may suppress the wide spectrum of cellular humoral responses drive autoimmunity in SjD. This study was phase 2, randomized, double-blinded, placebo (PBO)-controlled trial DAZ crossover stage two distinct populations...
Objective To investigate relationships between serum neurofilament light chain (sNfL), ubiquitin C-terminal hydrolase L1 (sUCHL1), tau (sTau) and glial fibrillary acidic protein (sGFAP) levels disease activity/disability in neuromyelitis optica spectrum disorder (NMOSD), the effects of inebilizumab on these biomarkers N-MOmentum. Methods N-MOmentum randomised participants to receive or placebo with a controlled period (RCP) 28 weeks an open-label follow-up ≥2 years. The sNfL, sUCHL1, sTau...
Inebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies. The relationship between B-cell, plasma-cell (PC), and immunoglobulin depletion longitudinal reductions NMOSD activity after inebilizumab was characterised post hoc exploratory analysis from N-MOmentum study (NCT02200770).Peripheral blood CD20+ B cells, PC gene signature, levels were assessed throughout (follow-up ≥2.5 years);...
<h3>Objective</h3> To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody, participants with neuromyelitis optica spectrum disorder (NMOSD). <h3>Methods</h3> Adults (N = 230) aquaporin-4 immunoglobulin G-seropositive NMOSD or -seronegative an EDSS ≤8 were randomized (3:1) to receive inebilizumab 300 mg placebo days 1 15. The controlled period...
The N-MOmentum trial, a double-blind, randomized, placebo-controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), enrolled participants who were aquaporin-4-immunoglobulin G (AQP4-IgG)-seropositive (AQP4+) or -seronegative (AQP4-). This article reports AQP4- participant outcomes.AQP4-IgG serostatus was determined for all screened by central laboratory, using validated, fluorescence-observation cell-binding assay. Medical histories and screening data...
The mechanisms that control N protein dependent antitermination in phage λ have counterparts many eukaryotic systems, including specific regulatory interactions of the with nascent RNA transcript. Here we describe and nonspecific binding modes N. These differ markedly affinity structure. protein, either free solution or as a complex RNA, lacks observable secondary tertiary structure binds sequences indiscriminately dissociation constant (Kd) ∼10-6 M. In contrast becomes partially folded at...
This randomized, controlled, forced‐switching, open‐label, parallel‐group study in 97 adult male and female smokers of conventional cigarettes evaluated biomarkers tobacco smoke exposure cardiovascular risk factors. After baseline measurements, were either switched to a second‐generation electrically heated cigarette smoking system (EHCSS) or continued for 12 months. Biomarkers factors measured at 0.5, 1, 2, 3, 4, 5, 6, 9, There was rapid sustained reduction all after switching the EHCSS,...
AMG X, a human neutralizing monoclonal antibody (mAb) against soluble protein, caused thrombocytopenia, platelet activation, reduced mean arterial pressure, and transient loss of consciousness in cynomolgus monkeys after first intravenous administration. In vitro, X induced activation platelets from macaque species but not humans or baboons. Other similar mAbs the same pharmacological target failed to induce these vivo vitro effects. addition, protein was known be expressed on platelets,...
Specific and processive antitermination by bacteriophage lambda N protein in vivo vitro requires the participation of a large number Escherichia coli proteins (Nus factors), as well an RNA hairpin (boxB) within nut site nascent transcript. In this study we show that efficient, though nonprocessive, can be induced concentrations alone, even absence site. By adding back individual components system, also with nut+ is much more effective than alone. This effect abolished if competed away from...
AMG 181 pharmacokinetics/pharmacodynamics (PK/PD), safety, tolerability and effects after single subcutaneous (s.c.) or intravenous (i.v.) administration were evaluated in a randomized, double-blind, placebo-controlled study.Healthy male subjects (n= 68) received dose of placebo at 0.7, 2.1, 7, 21, 70 mg s.c. (or i.v.), 210 420 i.v. placebo. Four ulcerative colitis (UC) 4, : female 2:2) (3:1). concentration, anti-AMG 181-antibody (ADA), α4 β7 receptor occupancy (RO), target cell counts,...
AMG 139 is a human anti-IL-23 antibody currently in phase II trial for treating Crohn's disease. To support its clinical development humans, vitro assays and vivo studies were conducted cynomolgus monkeys to determine the pharmacology, preclinical characteristics safety of this monoclonal antibody.